Project Grant R21AG102466
- The National Institute on Aging awarded $648,930 to the Regents of the University of California, doing business as University of California, Berkeley, on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop human stem cell-based microphysiological systems for aging research. The recipient will create a novel human aging-on-a-chip platform integrating fat and liver tissues derived from human induced pluripotent stem cells (hiPSCs) and microfluidics using serum from young...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $429,000 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate endothelial senescence intervention in limb muscle ischemia using exercise mimetics. The research will measure the effect of exercise mimesis on preventing or reversing muscle decline associated with peripheral arterial disease in aging populations. The project employs unique transgenic mouse lines, including...
- The National Institute on Aging awarded New York University $708,137 on February 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate technologies for probing the biophysical properties of aging cells. The funded work centers on developing genetically encoded multimeric particles (GEMs) as high-throughput microrheology probes to measure the physical properties of cell interiors—particularly within organelles including the nucleus, cytoplasm, endoplasmic reticulum,...
- The National Institute on Aging awarded Vanderbilt University Medical Center $3,079,819 for a Project Grant (R01AG092663) on January 1, 2026, under the Aging Research program (CFDA 93.866). The award funds research probing mechanistic links between endothelial aging and dementia. The recipient will passage human induced pluripotent stem cells differentiated to endothelial cells (hiPSC-ECs) obtained from healthy adults and individuals with vascular contributions to cognitive impairment and...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded Old Dominion University $160,000 on September 1, 2026, to develop and test a three-dimensional bioprinted mammary model system for investigating age-related cellular dysfunction and regenerative microenvironment mechanisms under the Aging Research program (CFDA 93.866). The project addresses molecular mechanisms underlying cellular and tissue rejuvenation through a regenerative microenvironment model....
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $518,555 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop spatially validated human lymphoid follicles-on-chip for modeling inflammaging and age-related immune dysfunction. The recipient will establish a lymphoid follicle organ-on-chip platform that recapitulates key hallmarks of human lymphoid function, including germinal center formation, AID expression, and antiviral antibody...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $533,500 to the Buck Institute for Research on Aging on July 15, 2026, under the Aging Research program (CFDA 93.866). The award funds examination of the role of autonomic innervation in muscle stem cell aging. The research investigates the functional link between autonomic nervous system neurons and muscle stem cells using Drosophila melanogaster as a model organism. The project will refine...
- The National Institute on Aging awarded Yale University $461,311 under the Aging Research program (CFDA 93.866) on May 1, 2026, to investigate vascular smooth muscle cell aging and epigenetic reprogramming as a pathway to reducing cardiovascular disease risk. The research examines how smooth muscle cells in arterial walls undergo epigenetic alterations—particularly DNA methylation changes—that drive vascular stiffening and atherosclerosis in aging. Yale's team has developed smooth muscle...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded The Medical College of Wisconsin, Inc. $618,354 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate endothelial cell senescence in tissue regeneration and repair. The award is a Project Grant (R01AG095980) with performance through May 31, 2031. The research examines how aging impairs angiogenesis—the formation of new blood capillaries—and how endothelial cell senescence contributes to deficiencies in organ regeneration and...
The National Institute on Aging, part of the Department of Health and Human Services, awarded $420,052 to Texas A&M Engineering Experiment Station on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop FlowGeroChips, a long-term microphysiological system for modeling age-related vascular dysfunction. FlowGeroChips replicates human aged arteriolar blood vessels using induced pluripotent stem cell-derived endothelial cells and vascular smooth muscle cells in a multicellular architecture. The system enables stable culture for up to 90 days and supports time-dependent assessment of endothelial cell-smooth muscle cell crosstalk under flow reversal conditions—the pathological retrograde and oscillatory blood flow associated with cardiovascular disease in aging. The approach uses a custom-engineered hemadyne perfusion system to reproduce clinically relevant flow reversal waveforms, addressing limitations of current preclinical in vitro models that cannot form fully confluent lumens or remain stable for extended periods. In Aim 1, the research team will engineer the FlowGeroChip with a cylindrical lumen of induced pluripotent stem cell-derived endothelial cells surrounded by extracellular matrix-embedded vascular smooth muscle cells, mimicking in vivo vessel structure. The chips will be exposed to normal versus reversed arterial periodic flow over 90 days, with the hypothesis that flow reversal will accelerate a shift toward a senescent phenotype. The award is a Project Grant with a period of performance from September 1, 2026, through August 31, 2028, performed at College Station, Texas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $420.1k | 8/21/26 |